Testing markers to predict chemo-radiation response in rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma (a specific type of rectal cancer found on biopsy).
- Your tumor is located within 12 cm of the anus (as measured by your doctor).
- Your cancer stage fits roughly stage II–III, specifically T3–T4 and/or N0–N1–2 (your staging report should match this range).
- You have not had any chemotherapy, radiation, or immunotherapy before starting the planned “neoadjuvant” (pre-surgery) treatment.
- You can understand and sign the informed consent form.
- Your bowel is not blocked and there is no risk of a blockage, and there is no bowel perforation.
- You have not had any other cancer diagnosed in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This study looks at how your genes and radiation-related factors affect how well rectal cancer responds to chemo and radiation given before surgery. The goal is to help personalize treatment and predict outcomes for people with locally advanced rectal cancer.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This study looks at whether a genetic test on a small sample of your tumor can predict how well you will respond to chemotherapy and radiation before surgery. This might help doctors choose the best treatment for you.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.